Richard L. Hurwitz, MD
Dr. Richard Hurwitz is a Co-Director of the Retinoblastoma Program. Dr. Richard Hurwitz studies the potential use of gene therapy for the treatment of ocular diseases. He has shown that a novel treatment for retinoblastoma using suicide gene therapy is safe and possibly effective in children. To further refine this therapeutic option, Dr. Hurwitz is studying the cellular origin of retinoblastoma and the differences between invasive and non-invasive forms of this disease. In addition, in vivo models of retinitis pigmentosa and macular degeneration are being used to develop gene therapy treatments for retinal degenerative diseases. The mechanism of adenoviral-mediated transgene expression in the ocular environment is being explored with goals of providing future molecular targets to modulate adenoviral-mediated gene therapy for both retinoblastoma and retinal degenerative diseases and possibly of controlling adenovirus infection in general.
Hematology Retinoblastoma Gene Therapy
Gene therapy for ocular diseases Cellular origin of retinoblastoma Retinal degenerative diseases
American Board of Pediatrics American Board of Pediatrics-Hematology/Oncology
* Texas Children's Hospital physicians' licenses and credentials are reviewed prior to practicing at any of our facilities. Sections titled From the Doctor, Professional Organizations and Publications were provided by the physician's office and were not verified by Texas Children's Hospital.